National Healthcare
NHC
221.19
-7.08
-3.10%
National Healthcare
US · NHC
#2365 by market cap
Listed 1970
221.19
-7.08
-3.10%
Live - 5344 symbols - heartbeat 364s ago
· 2026-10-08 04:03
Pre-market
219.64
-0.70%
After-hours
221.19
0.00%
Overnight
218.62
-1.16%
- Market cap
- 3.46B
- P/E (TTM)i
- 24.85
- P/Bi
- 3.09
- EPSi
- 7.67
- Div yieldi
- 1.17%
- 52W posi
- 86%
Reader sentiment
Are you bullish or bearish on NHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.80, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.09% YoY
Margins
- Gross margin
- 39.31%
- Operating margin
- 8.46%
- Net margin
- 7.91%
Key ratios & quality
- Enterprise valuei
- 3.28B
- PEG ratioi
- 0.33
- Altman Z-Scorei
- 6.80
PEG uses trailing P/E against the 3-year net income growth rate (74.87%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 980.35M | 996.38M | 1.03B | 1.07B | 1.09B | 1.14B | 1.31B | 1.52B |
| Gross profit | 397.63M | 403.55M | 371.41M | 344.88M | 388.11M | 429.20M | 487.01M | 596.70M |
| Selling & admin expenses | 40.92M | 40.52M | 40.49M | 40.82M | 40.98M | 41.53M | 43.18M | 46.23M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 60.77M | 52.17M | 49.55M | 60.00M | 28.73M | 57.46M | 89.90M | 128.35M |
| Pretax profit | 74.88M | 88.02M | 52.42M | 150.04M | 27.23M | 88.74M | 136.41M | 162.43M |
| Tax | 16.19M | 20.04M | 10.43M | 10.95M | 7.25M | 23.45M | 34.32M | 39.83M |
| Net profit | 58.70M | 67.98M | 41.99M | 139.09M | 19.98M | 65.29M | 102.09M | 122.61M |
| Basic EPS | 4 | 4 | 3 | 9 | 1 | 4 | 7 | 8 |
| Diluted EPS | 3.87 | 4.44 | 2.72 | 8.99 | 1.45 | 4.34 | 6.53 | 7.67 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 373.70M | 374.91M | 382.66M | 386.51M | 381.82M | 408.03M |
| Gross profit | 145.57M | 148.38M | 149.49M | 153.27M | 146.75M | 166.12M |
| Selling & admin expenses | 11.37M | 11.33M | 11.35M | 12.19M | 11.64M | 11.54M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 30.77M | 34.09M | 30.38M | 33.12M | 32.25M | 48.94M |
| Pretax profit | 43.72M | 32.17M | 54.41M | 32.13M | 44.82M | 54.01M |
| Tax | 11.43M | 8.06M | 13.40M | 6.94M | 8.71M | 13.47M |
| Net profit | 32.29M | 24.11M | 41.01M | 25.19M | 36.10M | 40.54M |
| Basic EPS | 2 | 2 | 3 | 2 | 2 | 3 |
| Diluted EPS | 2.07 | 1.52 | 2.50 | 1.58 | 2.27 | 2.54 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 322.01M | 341.05M | 456.76M | 426.64M | 353.93M | 406.24M | 424.41M | 461.82M |
| Cash & ST investments | 183.47M | 202.79M | 323.45M | 256.03M | 182.59M | 223.62M | 216.19M | 255.80M |
| Inventory | 7.47M | 7.44M | 8.78M | 8.58M | 7.09M | 7.39M | 9.04M | 7.80M |
| Total assets | 1.08B | 1.29B | 1.36B | 1.40B | 1.28B | 1.31B | 1.52B | 1.53B |
| Total current liabilities | 157.92M | 194.76M | 281.23M | 263.20M | 197.89M | 214.48M | 234.80M | 253.63M |
| Short-term debt | 3.92M | 38.41M | 29.87M | 32.27M | 34.06M | 30.21M | 39.34M | 41.11M |
| Long-term debt | 55.00M | -- | -- | -- | -- | -- | 129.50M | 32.50M |
| Total liabilities | 346,491,000.00 | 507,579,000.00 | 563,872,000.00 | 494,936,000.00 | 397,936,000.00 | 400,316,000.00 | 541,266,000.00 | 451,904,000.00 |
| Total equity | 734.46M | 779.07M | 798.26M | 908.46M | 877.51M | 910.48M | 983.16M | 1.07B |
| Retained earnings | 516.44M | 553.09M | 563.02M | 669.08M | 656.66M | 687.60M | 752.19M | 832.98M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 455.20M | 463.23M | 493.52M | 461.82M | 465.58M | 439.60M |
| Cash & ST investments | 243.17M | 257.63M | 297.38M | 255.80M | 258.35M | 210.19M |
| Inventory | 8.08M | 7.89M | 7.84M | 7.80M | 9.15M | 8.54M |
| Total assets | 1.55B | 1.56B | 1.57B | 1.53B | 1.52B | 1.54B |
| Total current liabilities | 239.23M | 268.75M | 282.36M | 253.63M | 250.83M | 236.11M |
| Short-term debt | 39.61M | 40.23M | 40.70M | 41.11M | 26.02M | 18.29M |
| Long-term debt | 126.50M | 102.50M | 65.63M | 32.50M | -- | -- |
| Total liabilities | 540,839,000.00 | 536,837,000.00 | 513,915,000.00 | 451,904,000.00 | 427,480,000.00 | 408,874,000.00 |
| Total equity | 1.01B | 1.03B | 1.06B | 1.07B | 1.10B | 1.13B |
| Retained earnings | 774.95M | 788.77M | 818.08M | 832.98M | 858.85M | 888.68M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 98.44M | 100.10M | 203.26M | 62.39M | 8.74M | 111.22M | 107.30M | 185.08M |
| Depreciation & amortization | 41.89M | 42.42M | 42.02M | 40.67M | 40.49M | 42.03M | 41.99M | 44.92M |
| Free cash flow | 68.66M | 73.70M | 181.39M | 23.00M | -21.46M | 83.32M | 79.70M | 148.63M |
| Dividends paid | -29.83M | -31.21M | -31.92M | -32.03M | -34.60M | -35.56M | -36.96M | -38.70M |
| Stock buybacks / issuance | 2.00M | 1.47M | 1.70M | 2.61M | -7.79M | -2.17M | 766.00K | -516.00K |
| Ending cash balance | 54.92M | 61.01M | 158.50M | 119.74M | 74.87M | 125.97M | 96.92M | 112.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 39.26M | 62.82M | 66.20M | 16.81M | 62.53M | 43.27M |
| Depreciation & amortization | 10.98M | 11.02M | 11.16M | 11.77M | 11.61M | 11.17M |
| Free cash flow | 33.12M | 52.62M | 56.49M | 6.41M | 52.89M | 30.74M |
| Dividends paid | -9.42M | -9.43M | -9.92M | -9.93M | -9.94M | -9.99M |
| Stock buybacks / issuance | -444.00K | 522.00K | -229.00K | -365.00K | -4.05M | -49.00K |
| Ending cash balance | 116.16M | 130.36M | 151.53M | 112.19M | 106.33M | 52.28M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.21 | 9.02 | 5.32 | 16.32 | 2.53 | 7.49 | 10.79 | 11.71 |
| ROA %i | 5.42 | 5.76 | 3.16 | 10.02 | 1.68 | 5.17 | 7.19 | 7.87 |
| ROIC %i | 6.95 | 7.14 | 3.84 | 13.12 | 1.84 | 6.08 | 8.87 | 9.99 |
| 5-year avg ROE %i | 8.04 | 8.19 | 7.70 | 9.41 | 8.28 | 8.14 | 8.49 | 9.77 |
| EBIT margin %i | 8.12 | 9.15 | 5.49 | 14.93 | 2.59 | 7.80 | 10.83 | 11.12 |
| FCF / sales %i | 7.00 | 7.40 | 18.50 | 2.27 | -- | 7.30 | 6.14 | 9.79 |
| Current ratioi | 2.04 | 1.75 | 1.62 | 1.62 | 1.79 | 1.89 | 1.81 | 1.82 |
| Quick ratioi | 1.79 | 1.53 | 1.47 | 1.34 | 1.43 | 1.55 | 1.50 | 1.56 |
| Debt / assetsi | 7.22 | 18.03 | 14.24 | 11.88 | 9.87 | 7.12 | 14.09 | 5.70 |
| LT debt / equityi | 10.11 | 24.87 | 20.64 | 14.88 | 10.51 | 6.95 | 17.90 | 4.30 |
| Interest coveragei | 16.94 | 29.07 | 38.47 | 178.56 | 49.37 | 274.88 | 33.99 | 26.50 |
| Revenue CAGR (3Y) %i | 2.64 | 2.56 | 0.58 | 1.03 | 2.54 | 5.19 | 8.69 | 12.21 |
| Net income CAGR (3Y) %i | 3.53 | 10.51 | -9.35 | 32.96 | -30.96 | 16.85 | -9.74 | 74.87 |
| FCF CAGR (3Y) %i | 40.16 | 37.61 | 42.93 | -30.56 | -- | -22.84 | 51.34 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.19 | 10.65 | 9.94 | 11.71 | 11.80 | 13.08 |
| ROA %i | 7.52 | 7.22 | 6.46 | 7.87 | 8.05 | 9.05 |
| ROIC %i | 9.49 | 9.35 | 8.34 | 9.99 | 10.22 | 11.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.96 | 10.16 | 9.61 | 11.12 | 11.01 | 12.05 |
| FCF / sales %i | 7.94 | 8.16 | 9.79 | 9.79 | 11.04 | 9.40 |
| Current ratioi | 1.90 | 1.72 | 1.75 | 1.82 | 1.86 | 1.86 |
| Quick ratioi | 1.61 | 1.49 | 1.52 | 1.56 | 1.58 | 1.47 |
| Debt / assetsi | 13.10 | 11.05 | 8.15 | 5.70 | 2.58 | 2.04 |
| LT debt / equityi | 16.25 | 12.95 | 8.30 | 4.30 | 1.22 | 1.17 |
| Interest coveragei | 24.31 | 18.10 | 18.26 | 26.50 | 37.07 | 73.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Inpatient Services is the largest reported line at 82.76% of revenue, across 3 reported segments.
- The next-largest line, Homecare and Hospice, is a distant second at 10.06% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Inpatient Services82.76%
Homecare and Hospice10.06%
All other7.18%
Quote time 2026-10-08 04:03:22 · For reference only, not investment advice and not tailored to your situation.